These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37122156)

  • 1. Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
    Bi Y; Wang P; Yu J; Wang Z; Yang H; Deng Y; Guan J; Zhang W
    CNS Neurosci Ther; 2023 Oct; 29(10):2998-3013. PubMed ID: 37122156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenobam modulates distinct electrophysiological mechanisms for regulating excessive gamma oscillations in the striatum of dyskinetic rats.
    Wang P; Dai W; Liu H; Liu H; Xu Y
    Exp Neurol; 2024 Aug; 378():114833. PubMed ID: 38782350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
    Dupre KB; Cruz AV; McCoy AJ; Delaville C; Gerber CM; Eyring KW; Walters JR
    Neurobiol Dis; 2016 Feb; 86():1-15. PubMed ID: 26586558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate.
    Wang Q; Chen J; Li M; Lv S; Xie Z; Li N; Wang N; Wang J; Luo F; Zhang W
    Neuropharmacology; 2019 Apr; 148():1-10. PubMed ID: 30612008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
    Ye T; Bartlett MJ; Sherman SJ; Falk T; Cowen SL
    Exp Neurol; 2021 Jun; 340():113670. PubMed ID: 33662379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
    Pinna A; Costa G; Serra M; Contu L; Morelli M
    Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
    Zheng C; Xu Y; Chen G; Tan Y; Zeng W; Wang J; Cheng C; Yang X; Nie S; Zhang Z; Cao X
    Neurobiol Dis; 2020 Jun; 139():104807. PubMed ID: 32088382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
    Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats.
    Tronci E; Fidalgo C; Stancampiano R; Carta M
    Behav Brain Res; 2015 Oct; 292():300-4. PubMed ID: 26119238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
    Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.